Biotech Most Volatile: Neuralstem (NYSEMKT:CUR), Aegerion Pharmaceuticals (NASDAQ:AEGR), Galena Biopharma Inc (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

Neuralstem, Inc. (NYSEMKT:CUR) announced that a study published in the peer-reviewed journal, PLOS ONE, showed that ischemic-stroke rats transplanted with Neuralstem Inc. (NYSEMKT:CUR)’s NSI-566 stem cells in the brain experienced functional improvements. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 3.74% in last session and finished the day at $3.88. Traded volume was 2.54million shares in the last session and the average volume of the stock remained … Continue reading Biotech Most Volatile: Neuralstem (NYSEMKT:CUR), Aegerion Pharmaceuticals (NASDAQ:AEGR), Galena Biopharma Inc (NASDAQ:GALE), Geron Corporation (NASDAQ:GERN)

FB Nasdaq FB Facebook

Biotech New Highs: Sinovac Biotech (NASDAQ:SVA), Neuralstem (NYSEMKT:CUR), Durata Therapeutics Inc (NASDAQ:DRTX), Recro Pharma (NASDAQ:REPH)

Sinovac Biotech Ltd (NASDAQ:SVA) a leading biopharmaceutical company in China has reported its fourth quarter and full year unaudited results for the period ending December 31, 2013. Sinovac Biotech Ltd. (NASDAQ:SVA) stock performance was 17.13% in last session and finished the day at $8.07. Traded volume was 4,876,818 million shares in the last session and the average volume of the stock remained 342.45 million shares. … Continue reading Biotech New Highs: Sinovac Biotech (NASDAQ:SVA), Neuralstem (NYSEMKT:CUR), Durata Therapeutics Inc (NASDAQ:DRTX), Recro Pharma (NASDAQ:REPH)

Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Shares of Neuralstem (NYSEMKT:CUR) , a clinical-stage biopharmaceutical company focused on treating central nervous system disorders through neural stem-cell therapies, advanced as much as 13% after reporting final phase 1 results utilizing NSI-566 in treating amyotrophic lateral sclerosis. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 12.05% in last session and finished the day at $4.37. Traded volume was 4,029,043 million shares in the last session and … Continue reading Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Today’s Watch List: Facebook Inc (NASDAQ:FB), GOL Linhas (NYSE:GOL), YY Inc. (NASDAQ:YY), Alexco Resource (NYSEMKT:AXU), Neuralstem, Inc. (NYSEMKT:CUR)

Facebook Inc (NASDAQ:FB) announced today the beginning of the new feature called Bandwidth Targeting. Advertisers now can target users based on their network connection speeds whether it’s mobile network 2G, 3G or 4G. Facebook Inc (NASDAQ:FB) belongs to Technology sector. Its net profit margin is 23.70% and weekly performance is -0.24%. On last trading day company shares ended up $74.63. Facebook Inc (NASDAQ:FB) distance from … Continue reading Today’s Watch List: Facebook Inc (NASDAQ:FB), GOL Linhas (NYSE:GOL), YY Inc. (NASDAQ:YY), Alexco Resource (NYSEMKT:AXU), Neuralstem, Inc. (NYSEMKT:CUR)

Bullish Stocks: Borderfree (NASDAQ:BRDR), Trivascular Technologies (NASDAQ:TRIV), Neuralstem (NYSEMKT:CUR), K2M Group Holdings Inc (NASDAQ:KTWO), Arc Logistics Partners LP (NYSE:ARCX)

As of late, it has definitely been a great time to be an investor in Borderfree Inc (NASDAQ:BRDR). The stock has moved higher by 22.7% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. Borderfree Inc (NASDAQ:BRDR) stock performance was … Continue reading Bullish Stocks: Borderfree (NASDAQ:BRDR), Trivascular Technologies (NASDAQ:TRIV), Neuralstem (NYSEMKT:CUR), K2M Group Holdings Inc (NASDAQ:KTWO), Arc Logistics Partners LP (NYSE:ARCX)

Healthcare Losers: CytRx (NASDAQ:CYTR), Trivascular Technologies (NASDAQ:TRIV), Neuralstem (NYSEMKT:CUR), Ventrus Biosciences Inc (NASDAQ:VTUS)

The company on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). CytRx Corporation (NASDAQ:CYTR) stock performance was -5.41% in last session and finished the day at $4.02. Traded volume was 9.62million shares … Continue reading Healthcare Losers: CytRx (NASDAQ:CYTR), Trivascular Technologies (NASDAQ:TRIV), Neuralstem (NYSEMKT:CUR), Ventrus Biosciences Inc (NASDAQ:VTUS)